These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease.
    Author: Nozaki Y, Fujita K, Yoneda M, Wada K, Shinohara Y, Takahashi H, Kirikoshi H, Inamori M, Kubota K, Saito S, Mizoue T, Masaki N, Nagashima Y, Terauchi Y, Nakajima A.
    Journal: J Hepatol; 2009 Sep; 51(3):548-56. PubMed ID: 19596472.
    Abstract:
    BACKGROUND/AIMS: Non-alcoholic fatty liver disease (NAFLD) is a hepatic manifestation of metabolic syndrome that is closely associated with multiple factors such as obesity, hyperlipidemia, type 2 diabetes mellitus and hypertension, making it difficult to treat NAFLD effectively using any monotherapy available to date. In this study, we propose a novel combination therapy for NAFLD comprising ezetimibe (EZ), a cholesterol absorption inhibitor, and acarbose (AC), an alpha-glucosidase inhibitor. METHODS: C57BL/6J mice were divided into five treatment groups as follows: basal diet (BD), high-fat diet (HFD) only, HFD with EZ (5mg/kg/day), HFD with AC (100mg/kg/day), and HFD with both EZ and AC for 24 weeks. RESULTS: Long-term combination therapy with EZ and AC significantly reduced steatosis, inflammation and fibrosis in the liver, compared with long-term monotherapy with either drug, in an HFD-induced NAFLD mouse model; the combination therapy also significantly increased the expression of microsomal triglyceride transfer protein (MTP) and peroxisome proliferators-activated receptor-alpha1 (PPAR-alpha1) in the liver, compared with either monotherapy, which may have led to the improvement in lipid metabolic disorder seen in this model. CONCLUSIONS: Combination therapy with EZ and AC for 24 weeks improved the histopathological findings in a mouse model of NAFLD.
    [Abstract] [Full Text] [Related] [New Search]